Your session is about to expire
← Back to Search
Acidosis avoidance for Kidney Failure (RADAR-A Trial)
N/A
Waitlist Available
Led By David Charytan, MD, MSc
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Maintenance hemodialysis therapy for end-stage renal disease
Age 18-85 years (subjects between 18-40 years old will be required to have at least one of the following: history of congestive failure, diabetes, coronary or peripheral vascular disease, or arrhythmia)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
RADAR-A Trial Summary
This trial will test how well a standardized algorithm for changing the dialysate can lower the risk of abnormal heart rhythms in people with kidney failure.
Eligible Conditions
- Kidney Failure
RADAR-A Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRADAR-A Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adherence With Proposed Interventions
Mean Monthly Duration of Clinically Significant Arrhythmia (CSA)
Number of Participants Enrolled Per Month
+2 moreSecondary outcome measures
All-Cause Mortality
Cardiovascular Mortality
Incidence of Hospitalization
+4 moreOther outcome measures
Association of demographic and pre-randomization factors with adverse events
Association of dialysis day, shift, and site with CSA
Association of dialysis day, shift, and site with adherence
+1 moreRADAR-A Trial Design
4Treatment groups
Experimental Treatment
Group I: Potassium Removal Maximization StrategyExperimental Treatment3 Interventions
Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
Group II: Potassium Gradient Minimization StrategyExperimental Treatment3 Interventions
Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
Group III: Alkalosis Avoidance StrategyExperimental Treatment3 Interventions
Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
Group IV: Acidosis Avoidance StrategyExperimental Treatment3 Interventions
Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Point of Care Testing
2018
N/A
~20
Cardiac Monitor
2018
N/A
~20
Find a Location
Who is running the clinical trial?
NYU Langone HealthLead Sponsor
1,358 Previous Clinical Trials
816,794 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,814 Previous Clinical Trials
47,290,856 Total Patients Enrolled
1 Trials studying Kidney Failure
402 Patients Enrolled for Kidney Failure
Duke UniversityOTHER
2,351 Previous Clinical Trials
3,409,527 Total Patients Enrolled
4 Trials studying Kidney Failure
1,595 Patients Enrolled for Kidney Failure
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger